A new series of studies provides the strongest evidence to date of cardiovascular risk associated with an artificial sweetener. The researchers call for revisiting food labeling requirements and more safety studies of sugar substitutes.
Menopausal Hormone Therapy and Heart Risk: Updated Guidance Is at Hand
A new review by an American College of Cardiology working group urges a nuanced approach in counseling women about the benefits and risks of hormone therapy from a cardiology perspective.
New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight
Randomized trial evidence that weight loss can yield cardiovascular benefits independent of antidiabetic effects has been elusive. Two major ongoing trials are likely to change that, with potentially big implications for clinical practice.
Statins Reduce Circulating TMAO, Suggesting Another Way They Curb Cardiovascular Risk
A new study suggests that plasma levels of this gut microbial metabolite might help further stratify cardiovascular risk when characterizing patients’ response to statin therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Beta-Blockers’ Efficacy May Be Partly Explained By Newly Discovered Gut Microbial Metabolite
A metabolite of the essential amino acid phenylalanine has been shown to play an important role in driving cardiovascular disease by enhancing platelet reactivity and acting upon platelet adrenergic receptors.
Cardiovascular Complications of Systemic Sclerosis: What to Look For
This automimmune condition isn’t traditionally associated with cardiac disease, but overt cardiac involvement confers a five-year mortality risk of up to 70%. Experts share screening and treatment guidance.
Managing Cardiovascular Risk in Diabetes Management
Patients live with the disease for decades and need increasingly complicated treatment regimens to attain glycemic goals. But other goals such as cardiovascular risk reduction, weight control, and avoidance of hypoglycemia also need consideration.
40% Reduction in Death and Major Cardiovascular Events Seen with Metabolic Surgery Vs. Usual Care
A large matched-cohort study in patients with type 2 diabetes and obesity finds that metabolic surgery confers significant improvements in all prespecified events plus marked reductions in weight, HbA1c, and use of diabetes and cardiovascular medications.
Teasing Out the Role of Red Meat and TMAO in Cardiovascular Risk
Two new studies take significant steps toward interventions to reduce cardiac risk in humans by reducing levels of the metabolite TMAO through diet manipulation or targeted therapies.
Distinctive Dozen: 12 Developments from 2016 Likely to Reshape Cardiovascular Practice
From heart benefits of diabetes drugs to leadless pacing to expanding populations for TAVR, 2016 was a dynamic year in cardiovascular care. Cleveland Clinic experts reflect on a dozen key developments.